SML1380

Sacubitril calcium salt

≥98% (HPLC)

• Sinônimo(s): (2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic acid ethyl ester, 4-[[(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid calcium salt, 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid; (2R,4S)-5-(Biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid ethyl ester, AHU-377 calcium salt, AHU377 calcium salt
• Fórmula empírica (Notação de Hill): C₂₄H₂₈NO₅ · 0.5Ca
• Número CAS: 1369773-39-6
• Peso molecular: 430.52
• Código UNSPSC: 12352200
• NACRES: NA.77

Propriedades

• Nível de qualidade: 100
• Ensaio: ≥98% (HPLC)
• forma: powder
• condição de armazenamento: desiccated
• cor: white to beige
• solubilidade: DMSO: 10 mg/mL, clear
• temperatura de armazenamento: −20°C

Descrição

Ações bioquímicas/fisiológicas

Sacubitril (AHU377) is a prodrug inhibitor of the membrane metallo-endopeptidase neprilysin. Sacubitril forms half of the heart failure combination drug LCZ696, along with the angiotensin-receptor blocker Valsartan. Sacubitril (AHU377) is cojnverted by esterases into the active inhibitor LBQ657, which prevents neprilysin′s degradation of atrial and brain natriuretic peptide, two blood pressure lowering peptides. The AHU377 valsartan combination drug LCZ696 showed a reduction in the risk of cardiovascular death of 20% compared to the standard ACE inhibitor enalapril, and also a 21% drop in the risk of hospitalization.

Informações de segurança

• Pictogramas: GHS06,GHS09
• Palavra indicadora: Danger
• Frases de perigo: H301,H400
• Declarações de precaução: P273 - P301 + P310 + P330
• Classificações de perigo: Acute Tox. 3 Oral - Aquatic Acute 1
• Código de classe de armazenamento: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe de risco de água (WGK): WGK 3
• Ponto de fulgor (°F): Not applicable
• Ponto de fulgor (°C): Not applicable